1. Home
  2. UMBF vs CORT Comparison

UMBF vs CORT Comparison

Compare UMBF & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UMB Financial Corporation

UMBF

UMB Financial Corporation

N/A

Current Price

$147.54

Market Cap

11.1B

Sector

Finance

ML Signal

N/A

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

N/A

Current Price

$111.86

Market Cap

9.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UMBF
CORT
Founded
1913
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.1B
9.7B
IPO Year
2007
2001

Fundamental Metrics

Financial Performance
Metric
UMBF
CORT
Price
$147.54
$111.86
Analyst Decision
Buy
Buy
Analyst Count
10
5
Target Price
$138.90
$96.50
AVG Volume (30 Days)
587.9K
1.3M
Earning Date
04-28-2026
04-30-2026
Dividend Yield
1.39%
N/A
EPS Growth
3.34
N/A
EPS
6.90
0.09
Revenue
N/A
$761,407,000.00
Revenue This Year
$18.07
$26.08
Revenue Next Year
$6.85
$26.98
P/E Ratio
$21.06
$1,267.14
Revenue Growth
N/A
12.79
52 Week Low
$103.38
$28.66
52 Week High
$150.00
$122.21

Technical Indicators

Market Signals
Indicator
UMBF
CORT
Relative Strength Index (RSI) 60.46 65.59
Support Level $122.02 $76.41
Resistance Level N/A $122.21
Average True Range (ATR) 3.24 5.21
MACD -0.03 0.55
Stochastic Oscillator 89.12 72.40

Price Performance

Historical Comparison
UMBF
CORT

About UMBF UMB Financial Corporation

UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking services and asset servicing to its customers in the United States and around the world. Its client base includes commercial, institutional, and personal customers. Along with its subsidiaries, the company operates in the following business segments: Commercial Banking, Institutional Banking, and Personal Banking. A majority of its revenue is generated from the Commercial Banking segment, which serves the commercial banking and treasury management needs of small to middle-market businesses through various products and services such as commercial loans, commercial real estate financing, commercial credit cards, letters of credit, loan syndication services, consultative services, and others.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Share on Social Networks: